Cabozantinib

Cabozantinib significantly improved PFS for patients with previously treated, progressive advanced extrapancreatic or pancreatic neuroendocrine tumors, according to phase 3 study results presented at ESMO Congress.

In a video interview, Sandra D’Angelo, MD, talked about a study of cabozantinib and temozolomide in patients with leiomyosarcoma and other soft tissue sarcomas, which was presented at the Connective Tissue Oncology Society Annual Meeting.

NASHVILLE, Tenn. — Zanzalintinib monotherapy showed promising antitumor activity among patients with previously treated clear cell renal cell carcinoma, according to findings presented at International Kidney Cancer Symposium: North America.

MADRID —Tian Zhang, MD, discussed the positive results presented at ESMO Congress on use of belzutifan combined with cabozantinib for patients with advanced clear cell renal cell carcinoma.

MADRID — Selpercatinib improved outcomes compared with cabozantinib or vandetanib for treatment of RET-mutant medullary thyroid cancer, according to randomized phase 3 study results presented at ESMO Congress.

National Prostate Cancer Awareness Month is observed every September.

The combination of cabozantinib and atezolizumab prolonged PFS compared with second novel hormonal therapy for men with metastatic castration-resistant prostate cancer, according to a topline data announcement.

In this video, Farshid Sadeghi, MD, discussed data for a study examining cabozantinib-resistant kidney cancer at American Urological Association Annual Meeting.

In this video, Farshid Sadeghi, MD, discussed data from the Cyto-KIK trial on renal cell carcinoma at American Urological Association Annual Meeting.

CHICAGO – Cabozantinib plus nivolumab showed promising efficacy in patients with papillary, unclassified or translocation-associated renal cell carcinoma, according to updated phase 2 study results presented at ASCO Annual Meeting.